Company profile

BIOGEN INC.

NASDAQ:BIIBBiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (38)

Asset	Stage	Revenue	Trials	Status
ADUHELM	approved	—	0	—
AVONEX	approved	—	18	approved
AVONEX	approved	—	18	approved
PLEGRIDY	approved	—	13	approved
PLEGRIDY	approved	—	13	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (412)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00664573	phase2	terminated	2007-11-01	2008-10-01	Biogen	104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
NCT02477800	phase3	terminated	2015-08-13	2019-08-08	Biogen	221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
NCT02484547	phase3	terminated	2015-09-15	2019-08-05	Biogen	221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
NCT03070132	phase3	withdrawn	2023-04-19	2025-10-14	Biogen	802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
NCT03637387	phase3	withdrawn	2023-03-01	2025-08-18	Biogen	802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia

FDA applications (13)

Application

Approved

Type

Applicant

Products

NDA 217369

2023-10-31

NDA

BIOGEN INC

BLA 761354

2023-09-29

BLA

BIOGEN MA INC.

NDA 215887

2023-04-25

NDA

BIOGEN MA INC

NDA 216718

2023-02-28

NDA

BIOGEN US CORPORATION

BLA 761178

2021-06-07

BLA

BIOGEN INC.